- Home
- FLC vs INBX Comparison
FLC vs INBX Comparison
Compare FLC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | INBX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.0M | 999.7M |
| IPO Year | 2003 | 2024 |
Fundamental Metrics
Financial Performance| Metric | FLC | INBX |
|---|---|---|
| Price | $17.17 | $69.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.7K | ★ 136.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 649.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.80 | $10.81 |
| 52 Week High | $18.09 | $94.57 |
Technical Indicators
Market Signals| Indicator | FLC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 34.09 | 40.74 |
| Support Level | $16.97 | $28.54 |
| Resistance Level | $17.24 | $85.97 |
| Average True Range (ATR) | 0.17 | 4.31 |
| MACD | -0.06 | -0.65 |
| Stochastic Oscillator | 26.69 | 15.04 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.